AKT1 and cancer: Interfering with Notch signaling on behalf of cancer chemotherapy may be a prototype case for future personalized cancer medicine; each patient will likely show a unique response pattern to Notch inhibitors, especially if combined with additional targeted drugs such as PI3Kinase, AKT, mTOR, and other inhibitors [25,93].